Scientists ID a protein that splices and dices genes
A novel finding by teams from the National Cancer Institute, The University of Texas Health Science Center at San Antonio and the University of Toronto, offers a clue as to how genes can have what you might call multiple personalities. The discovery reveals that the protein MRG15, which previously had been known to affect cell growth and aging, also directs the gene-splicing machinery. Olivia Pereira-Smith, Ph.D., a professor in the Department of Cellular and structural biology and the Sam and Ann Barshop Institute for longevity and Aging Studies at the UT Health Science Center San Antonio, has studied the function of MRG15 for more than 10 years.
As people or animals age, this gene-splicing machinery can go awry, producing nonsense proteins rather than the proper ones. These aberrant proteins can damage cells, possibly leading to cancer or other diseases of aging. The finding thus has potential implications for therapies to treat both cancer and aging, a Texas researcher said.
The Science paper's lead author is Reini F. Luco, Ph.D., a fellow in the laboratory of senior author Dr. Tom Misteli, Ph.D., at the National Cancer Institute (NCI). Other co-authors include Kaoru Tominaga, Ph.D., from the UT Health Science Center, and Benjamin J. Benclowe, Ph.D., and Qun S. Pan, Ph.D., from the University of Toronto.
"We've known for three or four years, from other analyses, that this protein was also involved in splicing, but we needed the expertise of Dr. Misteli's lab," Dr. Smith said. "Dr. Luco led the splicing studies on this project."
Dr. Tominaga, a faculty member of the Department of Cellular and Structural Biology and the Barshop Institute in San Antonio, said it may be possible to design cancer drugs to regulate MRG15's activity.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Validation of the dossier for drug approval of Biofrontera's BF-200 ALA successful
All tied up: Tethered protein provides long-sought answer
Naturalpha launches a clinical investigation center for nutrition
Biosignal: Collaboration with international company on agriculture applications - Evaluation for use in crop protection to be conducted over 9 months
Modified_starch
Indivumed to study the integrity of biospecimen sampling procedures for the U.S. National Cancer Institute - Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies

Surfers three times more likely to have antibiotic-resistant bacteria in guts
HNCOCA_experiment
Evotec completes acquisition of Just Biotherapeutics
Eicosapentaenoic_acid
Symbiosis_Institute_of_Geoinformatics
